MediWound secures additional DoD funding to advance NexoBrid for U.S. Army

MediWound announced that the U.S. Department of Defense – DoD -, through the Medical Technology Enterprise Consortium, or MTEC, has awarded MediWound an additional $6.7M in non-dilutive funding to develop NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army. The $14.4M project budget will advance the development and production of a new, temperature-stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings. Vericel Corporation holds an exclusive license encompassing the commercial and development rights to NexoBrid in North America as set forth in the license agreement between the Company and Vericel. The MTEC Research Project Award was granted by the DoD’s U.S. Army Medical Research and Development Command – USAMRDC – and funded by the Defense Health Agency through MTEC.